Advanced Pancreatic Carcinoma Clinical Trial
Official title:
Ensayo Fase II de selección Individualizada Del Tratamiento de Quimioterapia en Pacientes Con Carcinoma de páncreas Avanzado en función de la determinación de Dianas terapéuticas en el Tejido Tumoral
The purpose of this study is to determine the proportion of patients alive after 12 months of the beginning of the trial in patients with advanced pancreatic carcinoma individually selected and grouped according to the expression in tumor tissue for therapeutic targets.
Phase II, open two branches, in which conventional treatment is administered to patients
diagnosed with metastatic pancreatic carcinoma. Patients will be randomized (1:1) to a
treatment arm or control arm of experimental treatment guided by the therapeutic targets.
Patients in the control treatment arm will be treated with any of the schemes used in the
study according to the discretion of the physician responsible. Patients will be analyzed as
"intention to treat." In the experimental treatment arm (therapeutic targets) and within 15
days will determine the markers of therapeutic targets detailed in the protocol, either from
pre-existing tumor sample or a fresh sample obtained by biopsy. Based on the results of this
analysis, we prescribe a chemotherapy treatment determined for possible treatments currently
used in pancreatic carcinoma, gemcitabine, gemcitabine and capecitabine, gemcitabine and
erlotinib, FOLFIRINOX, FOLFOX, FOLFIRI.
Treatment duration is indefinite .
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05304936 -
HCW9218 for Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05620732 -
Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T
|
N/A | |
| Recruiting |
NCT05053971 -
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05733000 -
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT05143151 -
CD276-targeted Chimeric Antigen Receptor T Cells in Treatment With Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT05238831 -
SMMART Adaptive Clinical Treatment (ACT) Trial
|
Early Phase 1 | |
| Recruiting |
NCT05759923 -
First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours
|
Phase 1 | |
| Recruiting |
NCT05526443 -
Austrian Registry for Evaluation of Treatment Patterns and Outcome in Patients With Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
|
||
| Not yet recruiting |
NCT05257122 -
A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic Cancer
|
Phase 2 | |
| Completed |
NCT03033225 -
Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study
|
Phase 2 | |
| Recruiting |
NCT05969860 -
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
|
Phase 2 | |
| Recruiting |
NCT04550494 -
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
|
Phase 2 |